.svg)
Creating a culture, Perfecting quality.
Management Team
.svg){kind=icon}
Kari E. Krogstad joined Medistim as CEO in September 2009. She has more than 30 years of experience from the biomedical industry, from commercial leadership roles within the pharma, biotech and medtech sectors. Before joining Medistim, she spent 11 years at Dynal, where she also led Invitrogen Dynal in the role as General Manager after the acquisition from Invitrogen in 2005. Ms. Krogstad holds an M.Sc. degree in Molecular Biology from the University of Oslo as well as a Business degree from IHM Business School.
Kari E. Krogstad joined Medistim as CEO in September 2009. She has more than 30 years of experience from the biomedical industry, from commercial leadership roles within the pharma, biotech and medtech sectors. Before joining Medistim, she spent 11 years at Dynal, where she also led Invitrogen Dynal in the role as General Manager after the acquisition from Invitrogen in 2005. Ms. Krogstad holds an M.Sc. degree in Molecular Biology from the University of Oslo as well as a Business degree from IHM Business School.
Thomas Jakobsen joined Medistim as VP Finance in 2001. Previous experience includes Controller and Finance Manager at Sysdeco (1993-1998), and Finance Director of Microtronica Nordic (1998-2001), where he was responsible for building the finance team and converting to a new MIS system. Mr. Jakobsen holds a B.Sc. in Management from the Norwegian Business School (BI).
Thomas Jakobsen joined Medistim as VP Finance in 2001. Previous experience includes Controller and Finance Manager at Sysdeco (1993-1998), and Finance Director of Microtronica Nordic (1998-2001), where he was responsible for building the finance team and converting to a new MIS system. Mr. Jakobsen holds a B.Sc. in Management from the Norwegian Business School (BI).
Ole Arne Eiksund joined Medistim as CBDO in April 2022. He has more than 25 years of experience from the biomedical industry, with commercial leadership roles within the pharma and biotech sectors. Former positions include Commercial Director at GSK Pharma, VP Global Sales at Hofseth BioCare and before joining Medisitim he was the CEO of Arctic Bioscience. Mr. Eiksund holds a M.Sc. degree in Computational Science from the University of Manchester (UMIST) and an Executive MBA from Hult International Business School, London.
Ole Arne Eiksund joined Medistim as CBDO in April 2022. He has more than 25 years of experience from the biomedical industry, with commercial leadership roles within the pharma and biotech sectors. Former positions include Commercial Director at GSK Pharma, VP Global Sales at Hofseth BioCare and before joining Medisitim he was the CEO of Arctic Bioscience. Mr. Eiksund holds a M.Sc. degree in Computational Science from the University of Manchester (UMIST) and an Executive MBA from Hult International Business School, London.
Erik Swensen joined Medistim as VP Research & Development in 2002. Previous experience includes Development Engineer at ABB, Norway (1996-2002), where he participated in the development of advanced process control systems. From 1999 his focus was on developing ABB’s new control system for safety critical applications. Mr. Swensen holds a M.Sc. degree in Engineering Cybernetics from the Norwegian Institute of Technology (NTNU) in Trondheim.
Erik Swensen joined Medistim as VP Research & Development in 2002. Previous experience includes Development Engineer at ABB, Norway (1996-2002), where he participated in the development of advanced process control systems. From 1999 his focus was on developing ABB’s new control system for safety critical applications. Mr. Swensen holds a M.Sc. degree in Engineering Cybernetics from the Norwegian Institute of Technology (NTNU) in Trondheim.
Håkon Grøthe joined Medistim as CIO in April 2019. He is an experienced leader with a passion for increasing customer value through digital innovation. Håkon has put disruptive technologies such as AI, VR and Machine learning into work in his leadership roles from IT technology companies such as Impact Reality and Inspera. He also brings methodology experience relevant for agile processes, such as Google Sprint, Design Thinking and Kanban. Mr. Grøthe holds an M. Sc. degree in Industrial Economics/Computer Science from the Norwegian University of Science and Technology.
Håkon Grøthe joined Medistim as CIO in April 2019. He is an experienced leader with a passion for increasing customer value through digital innovation. Håkon has put disruptive technologies such as AI, VR and Machine learning into work in his leadership roles from IT technology companies such as Impact Reality and Inspera. He also brings methodology experience relevant for agile processes, such as Google Sprint, Design Thinking and Kanban. Mr. Grøthe holds an M. Sc. degree in Industrial Economics/Computer Science from the Norwegian University of Science and Technology.
Hæge J.K. Wetterhus joined Medistim as VP Marketing in 2010. She has more than 20 years of experience working with diagnostic, analytical and biotech device companies. Before joining Medistim, she worked for Invitrogen Dynal where she held a variety of leadership roles in strategic marketing, product development and business development in the area of life science and biotechnology – always with an international focus. Ms. Wetterhus is a business economist from BI, a chemical engineer from the Technical University of Bergen and holds a B.Sc. Honour in molecular biology from the University of Glasgow, UK.
Hæge J.K. Wetterhus joined Medistim as VP Marketing in 2010. She has more than 20 years of experience working with diagnostic, analytical and biotech device companies. Before joining Medistim, she worked for Invitrogen Dynal where she held a variety of leadership roles in strategic marketing, product development and business development in the area of life science and biotechnology – always with an international focus. Ms. Wetterhus is a business economist from BI, a chemical engineer from the Technical University of Bergen and holds a B.Sc. Honour in molecular biology from the University of Glasgow, UK.
Roger Morberg joined Medistim as VP Sales in June 2010. He has extensive experience from the healthcare industry and is a trained medical professional. Before joining Medistim he worked for Siemens Medical as Country Manager – Ultrasound. Mr. Morberg has previously held various roles within sales and senior management positions in Marquette Electronics, GE Healthcare and Hewlett Packard.
Roger Morberg joined Medistim as VP Sales in June 2010. He has extensive experience from the healthcare industry and is a trained medical professional. Before joining Medistim he worked for Siemens Medical as Country Manager – Ultrasound. Mr. Morberg has previously held various roles within sales and senior management positions in Marquette Electronics, GE Healthcare and Hewlett Packard.
Stephanie d’Avout Stenhagen joined Medistim in 2017 as Sales Manager Europe. With over two decades of experience in the medical device industry, she brings a wealth of expertise and strategic vision to drive Medistim’s sales efforts across the EMEA region. Prior to joining Medistim she held various leadership roles in strategic marketing and business expansion at Medtronic Inc. and served in a Global Marketing capacity for Nobel Biocare. Ms. Stenhagen holds an MBA in Marketing from the Fox School of Business at Temple University.
Stephanie d’Avout Stenhagen joined Medistim in 2017 as Sales Manager Europe. With over two decades of experience in the medical device industry, she brings a wealth of expertise and strategic vision to drive Medistim’s sales efforts across the EMEA region. Prior to joining Medistim she held various leadership roles in strategic marketing and business expansion at Medtronic Inc. and served in a Global Marketing capacity for Nobel Biocare. Ms. Stenhagen holds an MBA in Marketing from the Fox School of Business at Temple University.
Tone Veiteberg joined Medistim as VP Quality Assurance & Regulatory Affairs in 2013. She has more than 35 years of experience in Medical and Regulatory Affairs from the pharmaceutical and medical device industry, including Clavis Pharma, the Norwegian Association of Pharmaceutical Manufacturers, Leo Pharmaceuticals, and Glaxo/GlaxoWellcome (now GlaxoSmithKline). Ms. Veiteberg holds a M.Sc. in Pharmacy from the University of Oslo.
Tone Veiteberg joined Medistim as VP Quality Assurance & Regulatory Affairs in 2013. She has more than 35 years of experience in Medical and Regulatory Affairs from the pharmaceutical and medical device industry, including Clavis Pharma, the Norwegian Association of Pharmaceutical Manufacturers, Leo Pharmaceuticals, and Glaxo/GlaxoWellcome (now GlaxoSmithKline). Ms. Veiteberg holds a M.Sc. in Pharmacy from the University of Oslo.
Anne Waaler joined Medistim as VP Medical Department in 2016. She has more than 25 years of experience from the pharma and medtech industry and has previously worked for Nycomed and GE Healthcare, where she held a variety of different roles within medical, marketing and strategy. Ms. Waaler holds a M.Sc. in Pharmacy from the University of Oslo, an MBA from the Norwegian School of Management (BI) in Oslo, and an ESCP-EAP in Paris.
Anne Waaler joined Medistim as VP Medical Department in 2016. She has more than 25 years of experience from the pharma and medtech industry and has previously worked for Nycomed and GE Healthcare, where she held a variety of different roles within medical, marketing and strategy. Ms. Waaler holds a M.Sc. in Pharmacy from the University of Oslo, an MBA from the Norwegian School of Management (BI) in Oslo, and an ESCP-EAP in Paris.
Helge Børslid joined Medistim as Vice President Manufacturing in January 2017. Before joining Medistim, he was production manager at Halliburton, a company that offers products to the oil and gas industry. Previous experience ranges from test engineer to quality engineer at Norautron, Infineon Technologies, Kongsberg Maritime, and Sensor Development. Mr. Børslid holds a B.Sc. in Electronics Engineering from Vestfold University in Norway and a Master’s degree in Management from the Norwegian Business School (BI).
Helge Børslid joined Medistim as Vice President Manufacturing in January 2017. Before joining Medistim, he was production manager at Halliburton, a company that offers products to the oil and gas industry. Previous experience ranges from test engineer to quality engineer at Norautron, Infineon Technologies, Kongsberg Maritime, and Sensor Development. Mr. Børslid holds a B.Sc. in Electronics Engineering from Vestfold University in Norway and a Master’s degree in Management from the Norwegian Business School (BI).
Mike Farbelow joined Medistim as Vice President of the US sales team in May 2012. He has extensive sales and management experience from the medical device industry. He served for many years with Smith & Nephew’s Endoscopy division both as a sales representative and the Director of Sales for the central region. His most recent position prior to joining Medistim was with Richard Wolf USA where he served as their national sales manager in spinal endoscopy. Mr. Farbelow holds a degree in management from the University of Minnesota Carlson School of Management.
Mike Farbelow joined Medistim as Vice President of the US sales team in May 2012. He has extensive sales and management experience from the medical device industry. He served for many years with Smith & Nephew’s Endoscopy division both as a sales representative and the Director of Sales for the central region. His most recent position prior to joining Medistim was with Richard Wolf USA where he served as their national sales manager in spinal endoscopy. Mr. Farbelow holds a degree in management from the University of Minnesota Carlson School of Management.
Ole Jørgen Robsrud joined Medistim Norge AS as Managing Director in 2010. He comes from the position of Country Manager in HemoCue Norway and has 13 years of experience in the pharmaceutical company Pfizer, where he has held a variety of management positions in sales and marketing both on national and international level. Mr. Robsrud holds a M.Sc. in Business and Economics from the Norwegian Business School (BI) and the University of Florida.
Ole Jørgen Robsrud joined Medistim Norge AS as Managing Director in 2010. He comes from the position of Country Manager in HemoCue Norway and has 13 years of experience in the pharmaceutical company Pfizer, where he has held a variety of management positions in sales and marketing both on national and international level. Mr. Robsrud holds a M.Sc. in Business and Economics from the Norwegian Business School (BI) and the University of Florida.
Board of Directors
Øyvin Brøymer has served as Chair of Medistim since 2000. He works as an investor through his own company Intertrade Shipping AS and holds the position of Chair in Vistin Pharma ASA. Previous experience includes executive positions in The Aker Group, Hafslund Nycomed ASA, and Leif Höegh & Co ASA, as well as broad boardroom experience from many other companies. Mr. Brøymer holds a business degree from the Norwegian School of Management and an MBA from the University of Wisconsin. He is also Chair of the remuneration committee. His term expires in 2025.
Øyvin Brøymer has served as Chair of Medistim since 2000. He works as an investor through his own company Intertrade Shipping AS and holds the position of Chair in Vistin Pharma ASA. Previous experience includes executive positions in The Aker Group, Hafslund Nycomed ASA, and Leif Höegh & Co ASA, as well as broad boardroom experience from many other companies. Mr. Brøymer holds a business degree from the Norwegian School of Management and an MBA from the University of Wisconsin. He is also Chair of the remuneration committee. His term expires in 2025.
Anna Ahlberg is the CFO at the Swedish medical simulation company Surgical Science. Her previous career includes executive positions at several listed Swedish companies, such as med-tech companies Q-Med and Vitrolife. Ms. Ahlberg holds a MSc in Business Administration and Economics from the School of Business, Economics and Law, University of Gothenburg. She is an independent Board member and is a member of the audit committee. Her term expires in 2025.
Anna Ahlberg is the CFO at the Swedish medical simulation company Surgical Science. Her previous career includes executive positions at several listed Swedish companies, such as med-tech companies Q-Med and Vitrolife. Ms. Ahlberg holds a MSc in Business Administration and Economics from the School of Business, Economics and Law, University of Gothenburg. She is an independent Board member and is a member of the audit committee. Her term expires in 2025.
Ole Dahlberg is CEO at Curida, a life science company that develops and manufactures medicines, ensuring a safe supply of life-improving products. He has been in executive leadership roles both on the commercial side and in R&D at Dynal Biotech, German Biotech company Qiagen, and more recently for Thermo Fisher Scientific in the US. Mr. Dahlberg holds a MSc in Genetics and Marine Biology from the University of Oslo. His term expires in 2025.
Ole Dahlberg is CEO at Curida, a life science company that develops and manufactures medicines, ensuring a safe supply of life-improving products. He has been in executive leadership roles both on the commercial side and in R&D at Dynal Biotech, German Biotech company Qiagen, and more recently for Thermo Fisher Scientific in the US. Mr. Dahlberg holds a MSc in Genetics and Marine Biology from the University of Oslo. His term expires in 2025.
Gry Dahle is a cardiothoracic surgeon and consultant at Department of cardiothoracic surgery at Oslo University hospital. Her main interests are minimal invasive surgery, catheter treatment of valvular disease, heart failure and new innovations. Dr Dahle holds a PhD on Implementing TAVI in Rikshospitalet. She is the head of REK KULMU (ethical committee for medical devices) and deputy chairman of the Norwegian Medical Association Professional Board. She has a broad network in the international cardiothoracic society and is a member of several committees within EACTS, ESC and ICI. She is the Vice president of ISMICS. Her term expires in 2026.
Gry Dahle is a cardiothoracic surgeon and consultant at Department of cardiothoracic surgery at Oslo University hospital. Her main interests are minimal invasive surgery, catheter treatment of valvular disease, heart failure and new innovations. Dr Dahle holds a PhD on Implementing TAVI in Rikshospitalet. She is the head of REK KULMU (ethical committee for medical devices) and deputy chairman of the Norwegian Medical Association Professional Board. She has a broad network in the international cardiothoracic society and is a member of several committees within EACTS, ESC and ICI. She is the Vice president of ISMICS. Her term expires in 2026.
Jon Hoem is CEO of Pacertool, a company that develops a technology to select the right pacing approach for dyssynchronous heart failure patients. He has founded multiple early-stage cardiovascular medical device companies. Mr. Hoem was one of the early employees at Medistim, joining the company in 1994, and contributing to structuring Medistim’s initial sales effort in Europe, Japan, and the United States. He holds a MSc degree in microelectronics and organizational development from the Norwegian Institute of Technology (NTNU). His term expires 2024.
Jon Hoem is CEO of Pacertool, a company that develops a technology to select the right pacing approach for dyssynchronous heart failure patients. He has founded multiple early-stage cardiovascular medical device companies. Mr. Hoem was one of the early employees at Medistim, joining the company in 1994, and contributing to structuring Medistim’s initial sales effort in Europe, Japan, and the United States. He holds a MSc degree in microelectronics and organizational development from the Norwegian Institute of Technology (NTNU). His term expires 2024.
Tove Raanes has been a board member of Medistim since 2014. She is an advisor in the investment companies Dyvi Invest AS and Nore-Invest AS and serves as a board member in Bouvet ASA, Multiconsult ASA, and Krefting AS. Her experience includes strategy, finance, and business development from investment companies and management consulting from McKinsey & Company. Ms. Raanes holds a MSc from the Norwegian School of Economics (NHH). She is an independent board member and is Chair of the audit committee. Her term expires in 2026.
Tove Raanes has been a board member of Medistim since 2014. She is an advisor in the investment companies Dyvi Invest AS and Nore-Invest AS and serves as a board member in Bouvet ASA, Multiconsult ASA, and Krefting AS. Her experience includes strategy, finance, and business development from investment companies and management consulting from McKinsey & Company. Ms. Raanes holds a MSc from the Norwegian School of Economics (NHH). She is an independent board member and is Chair of the audit committee. Her term expires in 2026.
Peder Strand is employed as investment director at Seatankers Management. He serves as board member in Mowi ASA, ACapital Elimp Holdco, ACapital Medi Holdco, Nordic Ski and Mountains AB, Acapital ITAB Holdco, Echo Topco and Innsikt Holding. Mr. Strand holds a MSc from the Norwegian University of Science and Technology (NTNU). His term expires in 2026.
Peder Strand is employed as investment director at Seatankers Management. He serves as board member in Mowi ASA, ACapital Elimp Holdco, ACapital Medi Holdco, Nordic Ski and Mountains AB, Acapital ITAB Holdco, Echo Topco and Innsikt Holding. Mr. Strand holds a MSc from the Norwegian University of Science and Technology (NTNU). His term expires in 2026.
Need a full rundown of the MiraQ? Feel free to request a demo and we’ll be more than happy to show you our product range.
Økernveien 94, Oslo Norway
Org. nr: 936 656 013
(C) 2024 Medistim ASA
